Correlating Differences in the Surface Activity to Interface-Induced Particle Formation in Different Protein Modalities: IgG mAb Versus Fc-Fusion Protein
Molecular Pharmaceutics · 07.10.2024 · 21 (10) · 5088-5103
DOI: 10.1021/acs.molpharmaceut.4c00488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.08.2024. Verfasst von Valerie P Griffin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas 66045, United States. Hauptthemen laut MEDLINE: Immunoglobulin G, Immunoglobulin Fc Fragments, Polysorbates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Fulbright Association, Bristol Myers Squibb Foundation, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.
Abstract (Originalsprache)
The propensity of protein-based biologics to form protein particles during bioprocessing can be related to their interfacial properties. In this study, we compare the surface activity and interfacial film properties of two structurally different biologics, an IgG and Fc-fusion, in the absence and presence of interfacial dilatational stresses, and correlate these differences to their tendency to form interface-induced protein particles. Our results show that interface-induced particle formation is protein-dependent, with the Fc-fusion demonstrating greater interfacial stability. This observation can be correlated with faster adsorption kinetics of the Fc-fusion protein, and formation of a less incompressible film at the air-liquid interface. The addition of polysorbate 80 (PS80), commonly added to mitigate protein particle formation, led to a surfactant-dominant interface for quiescent conditions and coadsorption of protein and surfactant for the Fc-fusion when exposed to interfacial stress. On the other hand, for the IgG molecule, the surface always remained surfactant dominant. Image analysis demonstrated that PS80 was more effective in mitigating particle formation for the IgG than Fc-fusion. This suggests that a surfactant-dominant interface is necessary to prevent interface-induced protein particle formation. Further, while PS80 is effective in mitigating particle formation in the IgG formulation, it may not be the best choice for other protein modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas 66045, United States.
- Drug Product Development, Bristol Myers Squibb, New Brunswick, New Jersey 08901, United States.
ORCID-Profile: Estephanie L N Escobar, Ankit Kanthe, Prajnaparamita Dhar
Förderung
- Fulbright Association
- Bristol Myers Squibb Foundation
- Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior
Zitieren
APA
Griffin, V. P., Escobar, E. L. N., Ogunyankin, M. O., Kanthe, A., Gokhale, M., & Dhar, P. (2024). Correlating Differences in the Surface Activity to Interface-Induced Particle Formation in Different Protein Modalities: IgG mAb Versus Fc-Fusion Protein. Molecular Pharmaceutics, 21(10), 5088-5103. https://doi.org/10.1021/acs.molpharmaceut.4c00488
Vancouver
Griffin VP, Escobar ELN, Ogunyankin MO, Kanthe A, Gokhale M, Dhar P. Correlating Differences in the Surface Activity to Interface-Induced Particle Formation in Different Protein Modalities: IgG mAb Versus Fc-Fusion Protein. Molecular Pharmaceutics. 2024;21(10):5088-5103. doi:10.1021/acs.molpharmaceut.4c00488
BibTeX
@article{Griffin2024,
author = {Griffin, Valerie P and Escobar, Estephanie L N and Ogunyankin, Maria O and Kanthe, Ankit and Gokhale, Madhushree and Dhar, Prajnaparamita},
title = {Correlating Differences in the Surface Activity to Interface-Induced Particle Formation in Different Protein Modalities: IgG mAb Versus Fc-Fusion Protein},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {10},
pages = {5088--5103},
doi = {10.1021/acs.molpharmaceut.4c00488}
}
EUVIMED